** Shares of California-based drug developer Ideaya BiosciencesIDYA.O down 4.5% at $16.28
** IDYA receives breakthrough therapy designation for company's experimental drug, darovasertib, to treat a type of eye cancer called neoadjuvant uveal melanoma, before surgery
** Brokerage Leerink Partners says the majority of the neoadjuvant opportunity lies in the ~80% of patients scheduled for radiotherapy (both plaque and beam), which does not appear to be included in this designation
** "The drug will likely need to show an improvement over placebo in time" - Leerink Partners
** IDYA says the drug is currently being tested in a mid-stage trial and co plans to begin a late-stage study in H1 2025
** Neoadjuvant Uveal Melanoma affects 12,000 patients annually and is a high unmet medical need with no FDA-approved systemic therapies - IDYA
** Stock had fallen 35.8% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。